Janet S. Vergis
CIK 1590794 · last filed 2026-07-02
Janet S. Vergis is a corporate insider who has filed 80 SEC Form 4 insider transactions across 5 companies since 2014. The most recent filing shows the insider was granted $71.3K of CHD on Jul 2, 2026. Across all open-market trades the lifetime net is −$3.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.2M across reported positions. 11 SEC filings were submitted jointly with TEVA PHARMACEUTICAL INDUSTRIES LTD.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CHD price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
13320 BALLANTYNE CORPORATE PLACE
CHARLOTTE, NC 28277
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CHD | Director | 21,188 | $105.38 | $2.23M | -$3.65M | 31 | 2026-07-02 |
| XRAY | Director | 67,324 | $9.22 | $620.7K | $0 | 31 | 2026-06-05 |
| TEVA | Director | 73,697 | $39.95 | $2.94M | $0 | 10 | 2025-06-09 |
| AMRX | Director | 18,257 | $21.02 | $383.8K | $0 | 2 | 2019-05-08 |
| Impax Laboratories, LLC (IPXL) Delisted | Director | 12,150 | — | — | $0 | 3 | 2017-05-17 |
Recent Filings
80 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | CHD | Grant (A) | +736 | $71.3K | EDGAR |
| 2026-06-05 | XRAY | Grant (A) | +22,822 | $0 | EDGAR |
| 2026-05-06 | CHD | Grant (A) | +920 | $0 | EDGAR |
| 2026-02-05 | CHD | Mixed | — | -$665.9K | EDGAR |
| 2026-02-04 | CHD | Notice (144) | −12,960 | -$1.30M | EDGAR |
| 2026-01-13 | XRAY | Grant (A) | +200 | $0 | EDGAR |
| 2025-10-15 | XRAY | Grant (A) | +179 | $0 | EDGAR |
| 2025-07-15 | XRAY | Grant (A) | +139 | $0 | EDGAR |
| 2025-07-08 | CHD | Grant (A) | +729 | $70.1K | EDGAR |
| 2025-06-09 | TEVA | Mixed | +9,632 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.